SynCore to analyze cancer drug as it enters next phasesBy Kao Shih-ching / Staff reporterSynCore Biotechnology Co (杏國新藥) is planning an interim analysis of its pancreatic cancer treatment, SB05PC, later this month to determine the drug’s safety and efficacy. The company is conducting a phase III trial for the drug in Taiwan, the US, France, Hungary, South Korea, Russia and Israel, SynCore general manager Su Muh-hwan (蘇慕寰) told the Taipei Times on Thursday by telephone. As SB05PC is designed to prolong a person’s life, SynCore cannot enter into interim analysis of the drug until half of enrolled participants pass away, he said. SynCore had planned to enroll 218 participants, but the US Food and Drug Administration has approved adjusting that number based on the outcome of the interim analysis, Su said. If everything goes smoothly, SynCore plans to apply to the US regulator for marketing approval of the drug in 2022, he added.

Source: Taipei Times May 10, 2020 15:56 UTC